Idt Biologika
Idt Biologika, a prominent player in the biopharmaceutical industry, is headquartered in the United States and operates extensively across Europe and Asia. Founded in 1991, the company has established itself as a leader in the development and manufacturing of vaccines, biologics, and sterile injectables. Idt Biologika is renowned for its innovative approach to contract development and manufacturing, offering unique solutions that cater to the specific needs of its clients. The company’s state-of-the-art facilities and commitment to quality have positioned it as a trusted partner in the global market. With a focus on advancing public health, Idt Biologika has achieved significant milestones, including collaborations with major pharmaceutical companies and contributions to vaccine development. Its dedication to excellence and innovation continues to drive its success in the competitive biopharmaceutical landscape.
DitchCarbon Score
How does Idt Biologika's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Idt Biologika's score of 39 is higher than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Idt Biologika's reported carbon emissions
In 2023, IDT Biologika reported total carbon emissions of approximately 8,419,330 kg CO2e for Scope 1 and about 7,209,210 kg CO2e for Scope 2. This data reflects their commitment to transparency in emissions reporting, with no Scope 3 emissions disclosed. Comparatively, in 2021, the company recorded emissions of about 8,443,450 kg CO2e for Scope 1 and approximately 12,228,900 kg CO2e for Scope 2. This indicates a slight reduction in Scope 1 emissions over the two-year period, while Scope 2 emissions have decreased significantly. IDT Biologika has committed to achieving net-zero emissions across all scopes by 2050, as part of their Science Based Targets initiative (SBTi) commitments. This long-term target underscores their dedication to sustainability within the pharmaceuticals, biotechnology, and life sciences sector. The company is currently classified as "Committed" to near-term targets, indicating proactive steps towards reducing their carbon footprint. Overall, IDT Biologika's emissions data and climate commitments reflect a strategic approach to addressing climate change, aligning with industry standards and expectations for corporate responsibility.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2023 | |
|---|---|---|
| Scope 1 | 8,443,450 | 0,000,000 |
| Scope 2 | 12,228,900 | 0,000,000 |
| Scope 3 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Idt Biologika is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
